Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled time : 21:00 save search
California Water Service Group Moving Forward to Install PFAS Treatment Despite CPUC Dismissal of Request to Track Capital Costs in Pre-Approved Memorandum Account
Published: 2024-04-18 (Crawled : 21:00) - globenewswire.com
CWT | $46.57 0.74% 0.0% 2M
|
Utilities
|
| O: 0.9%
H: 2.19%
C: 2.19%
water california service group treatment
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Published: 2024-04-15 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.57 -0.22% -0.22% 160K
|
n/a
|
| O: 1.15%
H: 1.03%
C: -1.45%
disease treatment for meeting therapeutics
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
Published: 2024-03-28 (Crawled : 21:00) - globenewswire.com
APLT | $4.285 -3.92% -4.08% 770K
|
Health Technology
| Email alert
Add to watchlist
fda update treatment pdufa therapeutics
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-21 (Crawled : 21:00) - biospace.com/
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: 0.85%
H: 0.88%
C: 0.02%
vx-407 fda drug disease kidney treatment clearance application
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
Published: 2024-03-19 (Crawled : 21:00) - globenewswire.com
AEON | $4.01 -6.74% 0.5% 40K
|
|
| O: -4.03%
H: 7.45%
C: -8.9%
abp-450 fda update treatment biopharma meeting migraine
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Published: 2024-03-15 (Crawled : 21:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
LEGN | News | $45.205 -4.73% -4.97% 1.1M
|
Health Technology
|
| O: -0.27%
H: 4.91%
C: -2.9%
carvykti fda treatment
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
Published: 2024-03-04 (Crawled : 21:00) - globenewswire.com
APGE | $46.58 -6.41% -6.85% 260K
|
|
| O: 43.53%
H: 9.18%
C: -1.02%
apg777 conference report antibody dermatitis treatment trial results
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2024-03-01 (Crawled : 21:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
| Email alert
Add to watchlist
rybrevant fda first lung approved cancer cell treatment therapy
Armada Hoffler Announces Income Tax Treatment of Its 2023 Dividend Distributions
Published: 2024-02-23 (Crawled : 21:00) - globenewswire.com
AHH | $10.54 -1.5% 0.0% 310K
|
Finance
| Email alert
Add to watchlist
armada treatment
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
Published: 2024-02-22 (Crawled : 21:00) - globenewswire.com
CELC | $16.9 -1.97% -2.01% 90K
|
Commercial Services
|
| O: 0.33%
H: 3.46%
C: 1.93%
first cancer treatment trial
Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease
Published: 2024-02-14 (Crawled : 21:00) - globenewswire.com
CELU | News F | $3.385 5.45% 5.17% 36K
|
|
| O: -0.43%
H: 4.92%
C: 2.69%
disease ocular cell treatment
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
Published: 2024-02-08 (Crawled : 21:00) - globenewswire.com
CRVS | $1.58 3.27% 3.16% 91K
|
Health Technology
|
| O: 9.0%
H: 18.35%
C: 1.61%
drug granted cell treatment pharmaceuticals designation
Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
Published: 2024-02-08 (Crawled : 21:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: 0.26%
H: 3.36%
C: 1.98%
amx0035 treatment pharmaceuticals study
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
Published: 2024-02-05 (Crawled : 21:00) - globenewswire.com
RARE F | $44.26 -1.88% -1.92% 670K
|
Health Technology
|
| O: 0.67%
H: 2.0%
C: 1.84%
gtx-102 treatment designation prime
DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay
Published: 2024-02-01 (Crawled : 21:00) - biospace.com/
IMCR | $58.52 2.11% 2.07% 390K
|
Manufacturing
|
| O: 0.0%
H: 6.49%
C: 4.04%
cancer treatment diagnostics
Capital Southwest Announces U.S. Federal Income Tax Treatment of 2023 Dividends
Published: 2024-01-31 (Crawled : 21:00) - globenewswire.com
CSWC | $25.8 0.43% 0.43% 140K
|
Finance
|
| O: 0.53%
H: 0.0%
C: -1.54%
dividends treatment
Arbor Realty Trust Announces Tax Treatment of 2023 Dividends
Published: 2024-01-30 (Crawled : 21:00) - globenewswire.com
ABR | $13.02 -1.36% 0.31% 3.2M
|
Finance
|
| O: -1.41%
H: 0.38%
C: -5.0%
dividends treatment realty trust
New York Mortgage Trust Announces Tax Treatment of 2023 Dividend Distributions
Published: 2024-01-30 (Crawled : 21:00) - globenewswire.com
NYMT | $7.1 -1.39% -1.41% 470K
|
Finance
|
| O: -0.24%
H: 0.12%
C: -3.92%
treatment trust
UMH PROPERTIES, INC. ANNOUNCES TAX TREATMENT FOR 2023 DISTRIBUTIONS
Published: 2024-01-25 (Crawled : 21:00) - globenewswire.com
UMH 4 | $15.69 0.64% 0.0% 200K
|
Finance
|
| O: 0.52%
H: 0.39%
C: -1.09%
treatment
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Published: 2024-01-25 (Crawled : 21:00) - globenewswire.com
RARE F | $44.26 -1.88% -1.92% 670K
|
Health Technology
|
| O: 0.55%
H: 1.01%
C: -1.16%
ux701 disease treatment therapy study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.